 | |
- close
- close
|
The Value at Risk
Nov 20
Comment
Last week, under the cover of darkness and in an extraordinary show of Government incompetence, the FDIC seized United Commercial Bank. The problem is that Mingsheng, a Chinese bank, had already approached the Fed about a potential acquisition of...
Banking Business Review
Nov 20
Comment
The seizure of UCB to cost Minsheng $120m for the 9.9% stake it had in UCBH Holdings, the parent of UCB
FierceBiotech
Nov 17
Comment
Belgium's UCB is reengineering some of its research operations as it trims two percent of its global workforce. Its research division NewMedicines is being downsized, with 174 positions at its Braine-l'Alleud site in Belgium and 44 positions in...
The Economic Times
Nov 16
Comment
Denim jeans maker Levi’s and casual wear brand Benetton, both of which have been around since the 1990s, will cross the Rs 500-crore mark in turnover this year.
FierceBiotech
Nov 11
Comment
TRIN Pharma GmbH has appointed Stefan Wohlfeil as to be the company's new CEO. Release
RXi Pharmaceuticals has announced that Noah D. Beerman has joined the company as its new President and CEO. Release
Amarin Corporation has announced the...
Marketwire
Nov 10
Comment
BRUSSELS, BELGIUM -- (Marketwire) -- 11/10/09 -- UCB today announced the appointment of Ismail Kola, Executive Vice President, UCB & President of UCB New Medicines(TM),UCB's discovery research through to 'proof of concept' organization. Ismail Kola
Reuters
Nov 9
Comment
(Recasts; Adds conference call details, analysts comments,
updates share movement)
PR Newswire
Nov 3
Comment
ATLANTA, Nov. 3 /PRNewswire/ -- UCB, an active participant in the epilepsy community for more than a decade, is proudly launching a variety of patient-centered initiatives in honor of Epilepsy Awareness Month in November. These programs are the
PR Newswire
Oct 26
Comment
SAN DIEGO, Oct. 26 /PRNewswire/ -- New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients
Marketwire
Oct 22
Comment
BRUSSELS, BELGIUM -- (Marketwire) -- 10/22/09 -- * Financial performance in line with expectations * Strong early roll-out of major new products Cimzia®, Vimpat® and Neupro® * Diversification of debt begun with successful offering of EUR 500
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
| ||||||
|
|
